The Magazine for Sleep Professionals
Friday, August 28, 2026
Alkermes plc announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral […]
Evaluating the efficacy of a virtual care model using mandibular advancement devices for mild to moderate obstructive sleep apnea By Steven Alvarado, Peter Balacky, DDS, Edward Kim, Daniel Moradzadeh, Julieanna Gonzalez, and Martin L. Hopp, MD, PhD A prevalent sleep disorder affecting an estimated 54 million people in the […]
New survey results from the American Academy of Sleep Medicine explore the complex relationship between marijuana use and sleep. One-third (33%) of adults reported that their sleep is slightly or significantly better when they use marijuana. In contrast, 19% of adults reported either no impact (11%) or that their sleep is […]
Staying active is known to improve sleep, but the research findings are mixed regarding the best workout. Some studies say light walking or stretching is best, others prefer moderate-intensity workouts like jogging — and some even find that vigorous exercise such as swimming makes sleep worse. Resolving this discrepancy is […]
Alkermes plc presents new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of Neurology (AAN) 2026 Annual Meeting, taking place April 18-22, 2026 in Chicago. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment […]
Many more people work very early morning shifts than overnight ones, and a large proportion struggle with excessive sleepiness from shift work disorder, leading to problems with focus, performance and safety. A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early […]
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]
Narcolepsy is a chronic condition in which someone feels excessively sleepy, occasionally falling asleep without warning. This can have a major impact on their daily lives, affecting not only their education and employment, but also their ability to drive, their relationships, and their emotional health. “It’s quite striking when you’re […]
UCLA Research Brief A new study led by UCLA investigators shows that Verbal Reaction Time (VRT), the amount of time it takes a person to respond verbally, can be a marker of sleepiness in older adults. The study, which measured participants’ voice data through standardized cognitive assessments, show how VRT […]
